Determination of lower cut‐off levels of adalimumab associated with biochemical remission in Crohn's disease

BACKGROUND AND AIM: Adalimumab is administered and dosed using a standardized treatment regimen. Although therapeutic drug monitoring (TDM) may help optimize treatment efficacy, the lower cut‐off concentration of adalimumab needed to retain disease remission has not been established. This cross‐sect...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:JGH Open
Asıl Yazarlar: Carlsen, Arne, Omdal, Roald, Karlsen, Lars, Kvaløy, Jan Terje, Aabakken, Lars, Steinsbø, Øyvind, Bolstad, Nils, Warren, David, Lundin, Knut Erik Aslaksen, Grimstad, Tore
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Wiley Publishing Asia Pty Ltd 2019
Konular:
Original Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7273736/
https://ncbi.nlm.nih.gov/pubmed/32514446
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jgh3.12266
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller